Business Description
22nd Century Group Inc. is a US-based biotechnology firm that develops genetically engineered low-nicotine tobacco products aimed at reducing the health risks of traditional tobacco use. Founded in 1986 and currently led by CEO Michael Victus, the company capitalizes on its proprietary genetic technologies to secure licensing deals and strategic industry collaborations. With a market capitalization around $200 million and modest annual revenues, it has carved out a specialized niche in the tobacco and emerging cannabis sectors. The firm is actively expanding its product pipeline and pursuing regulatory and market opportunities to drive future growth.
Everything on 22nd Century Group Inc.
Financials
View financials ↗Earnings Transcripts
View all transcripts ↗Leadership & board
View leadership ↗Share Repurchase Program
No common-stock repurchase program; Item 5 (Issuer Purchases of Equity Securities) reported None. The only repurchase was the redemption at par of all outstanding Series A Convertible Preferred Stock issued in August 2025, in the amount of $9.65 million, funded with offering proceeds.
Named Competitors
Customer Concentration
Currently, a significant portion of our revenues (and corresponding accounts receivable) from manufacturing tobacco products are derived from a small number of large customers, and we do not have agreements with such customers requiring them to purchase a minimum amount of products from us.
Recent SEC Filings
See how Top Bucket AI works for your firm
Request DemoStay ahead of private markets
Research and market intelligence for private-markets professionals.
You're subscribed.
Thanks for signing up.